FDA approves Pfizer's Talzenna with Xtandi for metastatic prostate cancer with HRR gene mutations

The FDA approved Pfizer's TALZENNA (talazoparib), an oral PARP inhibitor, in combination with XTANDI (enzalutamide) for metastatic androgen pathway modulation-naive or -sensitive prostate cancer with HRR gene mutations, expanding treatment options for this genetic profile.

Detected & updated continuously · Source: Nebula